Sarepta’s CEO Douglas Ingram addressed recent concerns around transparency, defending the company’s disclosure practices amid criticism over delayed public acknowledgement of patient deaths in gene therapy trials. He highlighted Sarepta’s history of openness while acknowledging the challenges faced. Concurrently, the company announced a substantial restructuring to secure financial footing, including a 36% reduction in workforce and focusing efforts on its siRNA platform and core Duchenne portfolio. Despite setbacks, Sarepta projects continued revenue from its Duchenne muscular dystrophy therapies, including Elevidys and RNA-based PMO therapies.